Compare
Galectin Therapeutics Inc vs Propanc Biopharma, Inc. vs Lftd Partners Inc. vs Marker Therapeutics, Inc.
| Latest fiscal year | Galectin Therapeutics Inc GALT | Propanc Biopharma, Inc. PPCB | Lftd Partners Inc. LIFD | Marker Therapeutics, Inc. MRKR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $36.92M | $3.55M |
| Revenue growth (YoY) | n/a | n/a | -1.1% | -46.2% |
| Gross margin | n/a | n/a | 34.2% | n/a |
| Operating margin | n/a | n/a | 2.5% | -363.5% |
| Net margin | n/a | n/a | -67.3% | -343.0% |
| Net income | -$30.84M | -$58.92M | -$24.86M | -$12.16M |
| EPS (Diluted) | -$0.48 | -$14.85 | -$1.68 | -$0.79 |
| Operating cash flow | -$23.88M | -$405.2K | $1.32M | -$12.01M |
| Free cash flow | n/a | n/a | $1.20M | n/a |
| Cash & equivalents | $17.72M | n/a | $1.77M | $16.07M |
| Total assets | $19.53M | $19.63M | $19.27M | $19.07M |
| Total liabilities | $145.73M | $5.73M | $6.64M | $2.27M |
| Shareholders' equity | -$127.92M | $13.91M | $12.63M | $16.80M |
| Return on year-end equity | n/a | -423.7% | -196.8% | -72.4% |
| Shares outstanding | 65.20M | 11.61M | 14.82M | 16.70M |
Revenue, most recent five fiscal years
| Fiscal year | Galectin Therapeutics Inc | Propanc Biopharma, Inc. | Lftd Partners Inc. | Marker Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $36.92M Ended 2025-12-31 | $3.55M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $37.33M Ended 2024-12-31 | $6.59M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $51.61M Ended 2023-12-31 | $3.31M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $57.42M Ended 2022-12-31 | $3.51M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $31.66M Ended 2021-12-31 | $1.24M Ended 2021-12-31 |